← Back to Search

Other

Group 1: Zofin for Chronic Obstructive Pulmonary Disease

Phase 1 & 2
Waitlist Available
Research Sponsored by ZEO ScientifiX, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up screen, 4 months, and 12 months
Awards & highlights

Summary

This trial is testing an IV treatment called Zofin for people aged 40 to 80 who have COPD. The goal is to see if Zofin can help their lungs work better and make it easier for them to breathe. Participants will receive either Zofin or another treatment and be monitored over time to check the treatment's safety and effectiveness.

Eligible Conditions
  • Chronic Obstructive Pulmonary Disease (COPD)

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~screen, 4 months, and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and screen, 4 months, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety of Zofin
Secondary study objectives
% air in lung on CT Scan
CAT Assessment
CPET
+16 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Group 1: ZofinExperimental Treatment1 Intervention
Group 1 Treatment Arm (10 subjects): Zofin + Standard of care (SOC) Ten subjects will receive 1 mL of Zofin on Day 0, Day 4, and Day 8, containing 1-5 x 10\^11 particles/ml. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside. In addition to Zofin all subjects in this trial will receive SOC throughout the study period.
Group II: Group 2: PlaceboPlacebo Group1 Intervention
Group 2 Control Arm (10 subjects): Placebo + SOC Ten subjects will receive placebo on Day 0, Day 4, and Day 8, containing 101 mL of sterile saline at subject's bedside. In addition to placebo all subjects in this trial will receive SOC throughout the study period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Zofin
2022
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

ZEO ScientifiX, Inc.Lead Sponsor
3 Previous Clinical Trials
38 Total Patients Enrolled
Organicell Regenerative MedicineLead Sponsor
3 Previous Clinical Trials
38 Total Patients Enrolled
Natasha PhrsaiStudy DirectorProxima
1 Previous Clinical Trials
18 Total Patients Enrolled

Media Library

Zofin (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05643729 — Phase 1 & 2
Chronic Obstructive Pulmonary Disease Research Study Groups: Group 1: Zofin, Group 2: Placebo
Chronic Obstructive Pulmonary Disease Clinical Trial 2023: Zofin Highlights & Side Effects. Trial Name: NCT05643729 — Phase 1 & 2
Zofin (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05643729 — Phase 1 & 2
~11 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top